Tender detail
Conclusion of a non-exclusive pharmaceutical discount agreement for onabotulinumtoxin A
Summary
DAK-Gesundheit is procuring pharmaceutical discount agreements for the active substance botulinum toxin type A, limited to onabotulinumtoxin (ATC M03AX21). The agreements are planned for the period from 1 December 2026 to 30 November 2028 and are to be concluded with as many interested pharmaceutical companies as possible. They will end automatically when a new exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.